

Anti-CD276(B7H3)-DXD (Dar4)[Ifinatumab deruxtecan]

Product Information


Product Name	Anti-CD276(B7H3)-DXD (Dar4)[Ifinatumab deruxtecan]
Storage temp.	Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
Catalog# / Size	GM-87823AB-100 / 100 µg GM-87823AB-1mg / 1 mg

Antibody Information

Expression System	CHO
Purity	> 95% as determined by SDS-PAGE
Aggregation	< 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR)	4.0
Endotoxin	<1 EU/mg
Sterility	0.22 µm Filtered
Target	B7H3
Clone	Ifinatumab deruxtecan
Alternative Names	4Ig-B7-H3, B7-H3, CD276, B7RP-2
Source/Isotype	Monoclonal Human IgG1, κ
Application	Positive control of Cytotoxicity Assay
Description	Ifinatumab deruxtecan is an antibody-drug conjugate (ADC) that combines a specific monoclonal antibody with the potent cytotoxic agent deruxtecan, enabling precise delivery of the drug to a specific target on the surface of tumor cells, thereby effectively killing them. This drug specifically targets B7-H3 (CD276), a protein that is highly expressed in various tumors and has immunosuppressive functions. Due to B7-H3's tumor-associated expression and its role in regulating immune evasion, it has become an important target for ADC therapy. By targeting B7-H3 and delivering the cytotoxic agent, ifinatumab deruxtecan provides a precise and effective strategy for tumor treatment.
Formulation	10 mM NaAc-HAc, pH5.0


Version:3.2

SDS-PAGE





After SDS-PAGE under reducing conditions, the purity of the protein is greater than 95%.

SEC-HPLC



The purity of this product is greater than 95% verified by SEC-HPLC.

RP-HPLC



The drug-to-antibody ratio (DAR) of this product is 3.81.